A review of the latest decisions regarding the SPC waiver and its impact upon your generic and innovator life science exclusivity strategy.
Discover the intersection between regulatory and IP law with industry-led sessions on: clinical trials, data exclusivity, a Tecfidera case law review and the Pharmaceutical Strategy for Europe.
Understand the requirements for patentability within the life sciences industry with panel sessions on patent quality, G2/21, enablement and the PTAB.
Discuss the ways in which the UPC is impacting your life science strategy with an industry-led session and judges panel.
Over 65 In-House and Private Practice speakers are confrimed in this jam packed agenda
Unlock Strategic Insight: Get a full breakdown of sessions tackling the EU Pharma Package, SPC reform, antitrust, AI governance, and geopolitics so you know exactly where to focus your time across two content-packed days in Frankfurt.
See Who's Speaking: Preview the powerhouse speaker lineup of 50+ senior legal leaders from Regeneron, BioNTech, Polpharma, MSD, Roche, AbbVie, Novo Nordisk,Merck and more, spanning in-house counsel, regulators, and private practice.
Plan Your Networking: Explore 15 interactive roundtables, a Day 1 drinks reception, and dedicated networking breaks built into the agenda, designed to connect you with key stakeholders across innovator, generic, biotech, and science-driven organisations.
Tailor Your Attendance: With two parallel tracks covering IP & Regulatory Exclusivities alongside Market Access, Deals & Competition, downloading the agenda helps you map the most relevant sessions to your role, your priorities, and your challenges in 2026.